Public Consultation on Ban of E-Cigarettes in Brazil
According to an article in the Brazilian media on December 6, there will be an opportunity for various social groups in Brazil to openly participate in the discussion on whether e-cigarettes should be banned domestically. The Brazilian National Health Surveillance Agency (Anvisa) has published the schedule for the consultation in the Federal Official Gazette.
The Brazilian National Health Surveillance Agency has announced that a public consultation will begin on December 12th and will continue until February 9th of next year. The general public will have the opportunity to submit their opinions and suggestions through an online form. At the conclusion of the consultation, the agency will release a report detailing the findings of this process.
Since 2009, Brazil has banned the production, sale, import, and promotion of e-cigarette products. Despite this prohibition, the sale of e-cigarettes remains common nationwide.
The Brazilian Medical Association (AMB) and the Brazilian Association of Lung Diseases and Tuberculosis (SBPT), among other institutions, strongly advocate for maintaining the ban on the sale of e-cigarettes. Their main argument is that despite e-cigarettes not containing most of the toxic substances found in traditional cigarettes, they still contain nicotine and could potentially create a new generation of chemical addicts.
However, the opposing department argues that this measure banning e-cigarettes has no substantial effect. They believe that there should be established basic regulations to regulate the e-cigarette market.
Notice
1. This article is provided exclusively for professional research purposes related to industry, technology and policy. Any reference to brands or products is made solely for the purpose of objective description and does not constitute an endorsement, recommendation, or promotion of any brand or product.
2. The use of nicotine products, including but not limited to cigarettes, e-cigarettes, and heated tobacco products, is associated with significant health risks. Users are required to comply with all relevant laws and regulations in their respective jurisdictions.
3. This article is strictly restricted from being accessed or viewed by individuals under the legal age.
Copyright
This article is either an original work by 2Firsts or a reproduction from third-party sources with the original source clearly indicated. The copyright and usage rights of this article belong to 2Firsts or the original source. Unauthorized reproduction, distribution, or any other unauthorized use of this article by any entity or individual is strictly prohibited. Violators will be held legally responsible. For copyright-related matters, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have utilized AI to enhance translation and editing efficiency. However, due to technical limitations, errors may occur. Readers are advised to refer to the sources provided for more accurate information.
This article should not be used as a basis for any investment decisions or advice, and 2Firsts assumes no direct or indirect liability for any errors in the content.
